Nkarta Q1 FY26 net loss narrows to $27.8 million; G&A expenses drop to $5.9 million

• Nkarta posted a net loss of $27.8 million, or $0.37 per share, for Q1 2026.
• R&D expense edged up to $25 million, while G&A expense dropped to $5.9 million.
• Cash, cash equivalents, restricted cash, and investments fell to $266.7 million as of March 31, with runway expected to fund operations into 2029.
• Protocol changes agreed with FDA allow outpatient dosing in community settings, add an option to re-dose, remove overnight monitoring requirements, and expand Ntrust-2 to include rheumatoid arthritis.
• Enrollment continues at the 4 billion-cell dose level across Ntrust-1 and Ntrust-2, with initial clinical data planned for presentation at a medical meeting in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121601PRIMZONEFULLFEED9718713) on May 12, 2026, and is solely responsible for the information contained therein.